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Copeland et al Cardiothoracic TransplantationAccruing 36more patients over the period from 2003 to 2009
and including all patients from the FDA study have reduced
survival to transplantation by 12%, perhaps because we
have not censored any patients. Thus, this report is a true ac-
counting of all consecutive patients from 1993 to 2009.
One limitation of chart review databases such as ours is
that they rely on written documentation; consequently,
a few patients are not classified by functional status, not
all have preimplant hemodynamic monitoring, and many
do not have adequate data for calculating risk using one of
the many scales.4-8 Another limitation is that emergencies
often limit preimplant data acquisition.
Contraindications for implantation included chronic car-
diac cachexia, advanced physiologic age, chronic failure of
end organs incompatible with recovery, anticipated to be
impossible to recover to transplant candidate status, and
judged to have inadequate mediastinal size for the TAH.
Adverse events, including stroke in 8%, reoperation in
24.7%, device infection in 2.9%, and peripheral embolism
in 7.9%, were serious but acceptable in a group of critically
ill patients. Causes of death on device support were not sur-
prising with most secondary to multiple organ failure (13).
Other causes included pneumonia (6), sepsis (5), and neuro-
logic (4).CONCLUSIONS
There is a real clinical need for TAH support to rescue se-
lect patients with INTERMACS 1 profile from advanced
life-threatening cardiac failure. There are also a number
of specific scenarios that can best be treated with a TAH.
The option for out-of-hospital care decreases cost, improves
quality of life, and provides a long-term support option.
None of the patients in this study were on outpatient device
support. However, as more portable consoles become avail-
able and more centers are trained, the financial burden of
obligatory inpatient care will be removed and more patients
will be able to receive this therapy. From this single-center
inpatient experience, we expect that more lives will be
saved in the future.T
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Dr Hari Mallidi (Stanford, Calif). When you boil the study
down to its essence, it is basically a case series of poor quality
from an epidemiologic standpoint in terms of guiding further fu-
ture therapy, but it is a case series of approximately 100 patients
treated with INTERMACS class 1 status treated with TAH over
a period of 15 to 20 years. The devil is really in the details,
and unfortunately the details were not really provided in the
talk or the article.
There are really no data presented to convince the reader that
in fact these patients are not eligible for LVAD. Do you have
data concerning right ventricular function, pulmonary artery
pressure, right ventricular systolic work index, or any sort of
measure of right ventricular function or dysfunction at the time
of implant?
Dr Hannah Copeland. We do. We looked at all the pressures
and in our article referred to all of those publications. These data
have been reported by Copeland and colleagues.10 Right atrial
pressure was 20 mm Hg, pulmonary artery systolic pressure was
55 mm Hg, mean pressure was 44 mm Hg, and wedge pressure
was 30 mm Hg. There was no difference in this current experience
from that previously published. Further, as noted in the article, ofrdiovascular Surgery c Volume 143, Number 3 733
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X101 patients, 56 were failing on some other form of mechanical
support, had just had a cardiac arrest, or were failing on extracor-
poreal membrane oxygenation (ECMO). We also point out data
from the literature that clearly shows LVAD recipients with multi-
system organ failure have proven not to do well, and this forms the
basis for predictive scales that document poor outcomes in high-
risk LVAD recipients. For instance, a Lietz–Miller score in the
20s predicts a 30% 1-year survival with LVAD support. All of
our patients had multisystem organ failure or pathologic and ana-
tomic reasons for total heart replacement.
Dr Mallidi. In general, our experience has shown that patients
with elevated pulmonary artery pressures for the most part need
LVAD therapy alone. Their right ventricles can be managed with
inotropes or a temporary assist device to removal of the device
or weaning from inotropic therapy with just LVADs.
There is no cohort for comparison. Do you have any data of the
other ventricular assist device recipients at your center with re-
spect to those who just received LVADs or BiVADs but not neces-
sarily a TAH?
Dr H. Copeland. Contemporary experience with other devices
at the same institution was published comparing it with the
TAH.12 Briefly, survival was best with the TAH, followed by
LVAD and then BiVAD. At our institution, more than 350 devices
were implanted, including more than 150 LVADs, 82 BiVADs,
and 15 right ventricular assist devices during the time of our re-
ported TAH series. We did experience a 2-year time period
when the TAH was not available and incurred high mortality rates
attempting to salvage the same patient population with LVADs or
BiVADs.
DrMallidi. There were certain groups of patients in your study
who were not eligible for traditional ventricular assist devices.
These included those with transplant failure, chronic or acute re-
jection, hypertrophic cardiomyopathy, or complex congenital
anomalies. How many patients with the TAH have those indica-
tions for the device versus just the crash and burn case?
Dr H. Copeland. The majority were crash and burn cases.
There were a few failed Fontan operations, 1 peripartum cardio-
myopathy, and several intraoperative cardiac disasters that could
only be resolved with a TAH, and then as previously mentioned
and noted in the article, 26 patients were failing on a device
(mainly LVADS), 26 patients had just experienced cardiac arrests,
and 4 patients were failing ECMO. The rest were emergency
placements.
DrMallidi. The most recent patients with INTERMACS report
class 1 status had an overall survival of approximately 80% at 3
months. There was obviously a difference in survival between
thosewho just received an LVADand thosewho received a BiVAD,
and according to the latest INTERMACS report, the TAH seems to
have a survival in between the BiVAD and LVAD recipients, but
class 1 patients are class 1 patients; they are crash and burn. The
philosophy at many ventricular assist device centers has changed734 The Journal of Thoracic and Cardiovascular Surgfrommaximal support with devices for these patients to immediate
minimally invasive or less-invasive approaches to promote end-or-
gan recovery before a more definitive treatment. During the last 1.5
years at Stanford, we have probably had approximately 15 crash
and burn cases that were managed with temporary percutaneous
devices or ECMO as a bridge to another device. What we found
is 3 patients did not survive. Of the remaining 12, only 6 actually
ended up receiving a ventricular assist device of any kind, and of
those 6 only 2 ended up with a temporary right ventricular assist
device and the rest just had LVAD therapy. This experience is prob-
ably being recapitulated at many other centers. What this study
represents is a philosophy that has fallen out of favor at many cen-
ters in terms of the sicker the patient the greater the support that
needs to be administered immediately.
Dr H. Copeland. The INTERMACS database, as mentioned in
our article, for the TAH reflects the learning curve because a large
number of centers are starting their TAH experience, and often pa-
tient selection in this situation focuses on patients who we would
categorize as ‘‘compassionate need.’’ Therefore, I disagree with
your comment first of all.
In regard to how far you want to gowith these patients, I will tell
you this. I am a new mother of 6 months, and I am beyond hyper-
vigilant for all of my patients. I have a great respect for life. I
would hope that your comments do not reflect any less respect.
It is unfortunate if they (INTERMACS 1 cases) end up at your
center and you do not treat them and instead send them to hospice.
Using ECMO as a bridge to decision is valid and has been used by
our program many times. ECMO and low-flow (5 L/min) tempo-
rary devices may be inadequate to reverse advanced pathophysiol-
ogy and therefore mislead surgeons and physicians and only serve
as a pathway to patient death.
Dr Joseph Cleveland (Aurora, Colo). This patient population
remains challenging with regard to durable device implantation
and outcomes. We have just published in The Journal of Heart
and Lung Transplantation our analysis of the INTERMACs data-
base looking at BiVAD versus LVAD recipients. The outcomes are
clearly inferior for the BiVAD recipients, and it gets down to again
not the pump but the population. This patient group is extremely
difficult. They are extremely high risk, and I think we need a better
paradigm than implantable durable pumps. This strategy of Bi-
VAD or TAH is just not going to result in good outcomes for
this patient population and in particular for the INTERMACs level
1 cases. Our center has moved away from placing durable pumps
in these patients and toward ECMO or other short-term assist de-
vice strategies. It is incredibly difficult to sometimes walk away
from people, but at the same time we are going to be the group
faced with responsibly using this technology and making sure
that the technology remains viable. We cannot be operating on pa-
tients who are unsalvageable to attempt heroic operations with Bi-
VADs or artificial hearts because the data do not justify this
practice.ery c March 2012
